Side-by-side comparison of AI visibility scores, market position, and capabilities
Seattle application delivery and security (NASDAQ: FFIV) ~$2.8B revenue; BIG-IP ADC + NGINX + F5 Distributed Cloud, ADSP Partner Program (CrowdStrike/DigiCert), hardware-to-SaaS transition competing with Cloudflare.
F5, Inc. is a Seattle, Washington-based application security and delivery technology company — publicly traded on NASDAQ (NASDAQ: FFIV) as an S&P 500 Information Technology component — providing application delivery controllers, multi-cloud application security, load balancing, and distributed cloud security services to enterprise customers managing applications across on-premises data centers, private clouds, and public cloud environments (AWS, Azure, Google Cloud) through approximately 6,000 employees worldwide. F5's product portfolio spans hardware BIG-IP appliances (application delivery controllers providing load balancing, SSL offloading, web application firewall, and traffic management in on-premises data centers), software BIG-IP Virtual Edition (the same application delivery functionality running as virtual machines in private clouds), NGINX (the open-source web server and reverse proxy acquired in 2019 for $670M, with NGINX Plus as the commercial offering), and F5 Distributed Cloud Services (multi-cloud networking, bot defense, API security, and DDoS mitigation delivered as-a-service). F5 launched the Application Delivery and Security Platform (ADSP) Partner Program with inaugural technology partners including AppViewX, CrowdStrike, DigiCert, Kasm Technologies, Keyfactor, MazeBolt, and OPSWAT — integrating certificate lifecycle management, endpoint detection, DDoS protection, and application security testing into a unified platform. CEO François Locoh-Donou leads F5's multi-year transition from a hardware-dominant business (where BIG-IP physical appliances generated 60%+ of revenue at peak) toward a software and SaaS-led model that grows recurring revenue as enterprises migrate applications to cloud environments. In fiscal year 2024, F5 reported revenue of approximately $2.8 billion.
Global pharma company with $55B 2024 revenue; successfully diversifying beyond Humira with Skyrizi, Rinvoq, and $8.7B Cerevel neuroscience acquisition.
AbbVie is a global research-based biopharmaceutical company focused on developing treatments for complex and serious diseases including immunology, oncology, neuroscience, aesthetics, and eye care. Spun off from Abbott Laboratories in 2013 and headquartered in North Chicago, Illinois, AbbVie rapidly became one of the world's top pharmaceutical companies on the strength of Humira — the world's best-selling drug for over a decade with peak annual sales exceeding $20 billion. AbbVie is listed on the NYSE and is a component of the S&P 500 and Dow Jones Industrial Average.
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.